Immunovant IMVT 深 沪
已收盘 08-07 16:00:00 美东时间
39.95
+0.210
+0.53%
华盛通- 最 高40.33
- 今 开39.86
- 成交量 77.32万股
- 最 低 37.98
- 昨 收 39.74
- 总市值 467.42万
- 52周最高 41.23
- 市盈率 静 --
- 换手率 660.83%
- 52周最低 14.47
- 委 比 -69.28%
- 总股本 0.00亿
- 历史最高 53.75
- 量 比 0.94
- 振 幅 5.91%
- 历史最低 1.10
- 每 手 1
- 风险率 7.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunovant Stock Surges Despite Disappointing Earnings Miss
Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expected fourth‑quarter loss.
05-21 01:09
Crude Oil Down 5%; Lowe's Posts Upbeat Earnings
US stocks rise with Dow gaining 1% on Wednesday. The Nasdaq and S&P 500 also saw gains. Lowe's Companies reported upbeat earnings.
05-21 00:16
Immunovant Q4 EPS $(0.73) Misses $(0.60) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.60) by 21.67 percent. This is a 14.06 percent decrease over losses of $(0.64) per share from the
05-20 19:01
Market-Moving News for April 2nd
GSAT: 24% | Globalstar shares are trading higher following reports suggesting that Amazon is in discussions to acquire the company. IMVT: -17% | Immunovant shares are trading lower after the company
04-02 19:17
Immunovant Q3 Earnings Assessment
Immunovant (NASDAQ:IMVT) announced its Q3 earnings on Friday, February 6, 2026 ...
02-06 20:02
Roivant Signals Major Pipeline Momentum With Accelerated Timelines
Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.
2025-12-12 02:39
Immunovant Q2 EPS $(0.73) Misses $(0.72) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.72) by 0.69 percent. This is a 1.35 percent increase over losses of $(0.74) per share from the
2025-11-10 20:03
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Insights into Immunovant's Upcoming Earnings
Immunovant (NASDAQ:IMVT) will release its quarterly earnings report on Monday, ...
2025-11-07 22:02
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
Immunovant's new management team is advancing IMVT-1402 for six indications, including potentially registrational studies in Graves’ disease and Sjögren’s disease. Positive data from batoclimab trials in MG and CIDP show deeper IgG reductions linked to better outcomes, suggesting IMVT-1402's best-in-class potential. The company has a strong cash position to support ongoing programs through 2027.
2025-05-29 11:00
